Constitutive activation of integrin αvβ3 contributes to anoikis resistance of ovarian cancer cells-Reference-Cited by-同舟云学术

Constitutive activation of integrin αvβ3 contributes to anoikis resistance of ovarian cancer cells

Published:2020-12 Issue:2 Volume:15 Page:503-522
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Dolinschek Romana¹,Hingerl Julia¹,Benge Anke¹,Zafiu Christian²,Schüren Elisabeth¹,Ehmoser Eva‐Kathrin³,Lössner Daniela⁴,Reuning Ute¹^ORCID

Affiliation:

1. Department for Obstetrics & Gynecology Clinical Research Unit Technische Universität München Germany

2. Department of Water, Atmosphere, and Environment University for Natural Resources and Applied Life Sciences (BOKU) Vienna Austria

3. Department for Nanobiotechnology Institute for Synthetic Bioarchitectures University for Natural Resources and Applied Life Sciences (BOKU) Vienna Austria

4. Faculties of Engineering and Medicine Nursing & Health Sciences Monash University Melbourne Vic. Australia

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12845

Reference93 articles.

1. Multicellular spheroids in ovarian cancer metastases: Biology and pathology

2. Getting to know ovarian cancer ascites: opportunities for targeted therapy‐based translational research Front;Ahmed N;Oncol,2013

3. Integrins in cancer: biological implications and therapeutic opportunities

4. Integrin regulation

5. The final steps of integrin activation: the end game

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Remodeling of tumor microenvironment by extracellular matrix protein 1a differentially regulates ovarian cancer metastasis;Cancer Letters;2024-08

2. Identification and validation an anoikis-related gene signature for clinical diagnosis, prognosis and treatment of patients with hepatocellular carcinoma;2024-07-02

3. Targeting anoikis resistance as a strategy for cancer therapy;Drug Resistance Updates;2024-07

4. Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer;Advanced Healthcare Materials;2024-06-06

5. Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer;npj Precision Oncology;2024-06-05